Abstract

The aim of this study was to determine whether post-hypoxic frequency decline (PHFD) requires central activation of α 2-adrenergic receptors. PHFD is defined as the undershoot in respiratory frequency that occurs immediately following brief hypoxic periods. Adult anesthetized, vagotomized rats were exposed to hypoxia (8% O 2, mean=45 s) before and after intracerebroventricular (i.c.v.) infusion of vehicle or α 2-antagonist. The efficacy of the i.c.v. antagonist was assessed by recording the response to intravenous injection of α 2-agonist before and after the infusion. We compared breathing frequencies before, during, and after hypoxia, both before and after treatments. The decline in breathing frequency after hypoxia was not prevented by the α 2-antagonists, RX 821002 or SK&F-86466. Guanabenz, an α 2-agonist, prolonged baseline expiration and potentiated PHFD. Prior treatment with SK&F-86466 blocked the agonist-evoked response which was also reversed by subsequent administration of SK&F-86466. We conclude that PHFD does not require the activation of α 2-adrenergic receptors, but that α 2-adrenergic receptors can modulate resting and post-hypoxic respiratory frequency.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.